Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Tularik Inc. (TLRK) -- Ignore unavailable to you. Want to Upgrade?

To: tommysdad who wrote (19)	12/22/1999 8:34:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 598

>> A small thing, maybe << Not a small thing to me. I can think of one CEO that wishes that he'd been less casual. I notice the same stuff. >> let's just say TLRK seems "richly valued" << Agree, but at least we're talking pharma margins, if and when. Take a look at CMDX.

To: tommysdad who wrote (19)	12/30/1999 4:01:00 AM
From: Frank Stein	Respond to of 598

I saw that in the SEC filing, but i also found this: " Between January 1995 and February 1998, we forgave $165,968 of the principal and $24,780 of the interest due on a loan of $240,000 we provided to Dr. McKnight in June 1992 to cover housing differential costs in connection with his move to California from another state. In addition, we have paid $153,082 to Dr. McKnight to offset taxable income to him arising as a consequence of our loan forgiveness. No amounts are due by Dr. McKnight on this loan." Frank